KEMRI-Wellcome Trust Collaborative Research Program
Quick facts
Marketed products
- hepatitis A vaccine, DTaP, PCV10 · Immunology
This is a combination vaccine that stimulates the immune system to produce antibodies against hepatitis A virus, diphtheria, tetanus, pertussis, and pneumococcal pathogens. - PCV10 and DTaP · Immunology
PCV10 and DTaP is a combination vaccine that stimulates the immune system to produce antibodies against pneumococcal serotypes and diphtheria, tetanus, and pertussis toxins.
Phase 3 pipeline
- Benzyl penicillin · Infectious Disease
Benzyl penicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- KEMRI-Wellcome Trust Collaborative Research Program portfolio CI brief
- KEMRI-Wellcome Trust Collaborative Research Program pipeline updates RSS
Frequently asked questions about KEMRI-Wellcome Trust Collaborative Research Program
What are KEMRI-Wellcome Trust Collaborative Research Program's marketed drugs?
Top marketed products include hepatitis A vaccine, DTaP, PCV10, PCV10 and DTaP.
What is KEMRI-Wellcome Trust Collaborative Research Program's pipeline?
KEMRI-Wellcome Trust Collaborative Research Program has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Benzyl penicillin.
Related
- hepatitis A vaccine, DTaP, PCV10 · Immunology
- PCV10 and DTaP · Immunology
- Sector hub: All tracked pharma companies